| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Levine J | |
| Gershon S | |||
| Chengappa KN | |||
| Cole DP | |||
| P2860 | cites work | Paroxetine efficacy in the treatment of generalized anxiety disorder | Q28241959 |
| Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey | Q28258215 | ||
| Double-blind, controlled trial of inositol treatment of depression | Q34058748 | ||
| A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder | Q34163986 | ||
| Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis | Q34315144 | ||
| Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam | Q34343222 | ||
| Phenelzine vs atenolol in social phobia. A placebo-controlled comparison | Q34374338 | ||
| Benzodiazepines for depression? A review of the literature | Q34386328 | ||
| Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder | Q34721772 | ||
| Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment | Q38595004 | ||
| Benzodiazepines in Depressive Disorders | Q39216756 | ||
| Comorbidity and social phobia: evidence from clinical, epidemiologic, and genetic studies | Q40540272 | ||
| Benzodiazepines as antidepressants: does GABA play a role in depression? | Q40952779 | ||
| Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline | Q41334611 | ||
| Panic disorder and social phobia: possible implications of comorbid depression for drug therapy | Q41478651 | ||
| Major depression and generalized anxiety disorder. Same genes, (partly) different environments? | Q42003805 | ||
| Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression | Q42201119 | ||
| Symptoms of anxiety and symptoms of depression. Same genes, different environments? | Q45058413 | ||
| Double-blind pilot trial of desipramine versus fluoxetine in panic patients | Q46143700 | ||
| One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites | Q47375366 | ||
| Blunted growth hormone response to clonidine in panic disorder patients | Q48304195 | ||
| Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications | Q48786821 | ||
| Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor | Q48887380 | ||
| Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study | Q48932274 | ||
| Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients | Q49024832 | ||
| Alprazolam vs amitriptyline in depressions with reduced REM latencies | Q49030427 | ||
| Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients | Q49158235 | ||
| Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. | Q51034646 | ||
| Treatment of posttraumatic stress disorder with amitriptyline and placebo. | Q51169063 | ||
| Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety. | Q51229002 | ||
| Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. | Q51271294 | ||
| Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. | Q51784295 | ||
| Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. | Q52048160 | ||
| Psychiatric reaction patterns to imipramine | Q52139111 | ||
| Continuing dialogue on incentive bias. | Q52899002 | ||
| Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder | Q54012010 | ||
| Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. | Q55065131 | ||
| Pharmacotherapy of Social Phobia | Q56057740 | ||
| Clinical Effects of the 5-HT1A Partial Agonists in Depression | Q56431858 | ||
| Buspirone | Q56442372 | ||
| A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder | Q57697275 | ||
| Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group | Q67961275 | ||
| Alprazolam compared to amitriptyline in the treatment of major depression | Q69183343 | ||
| A controlled trial of desipramine in 18 men with posttraumatic stress disorder | Q69491772 | ||
| Studies in the classification of affective disorders. The relationship between anxiety states and depressive illnesses. I | Q70479379 | ||
| Studies in the classification of affective disorders. The relationship between anxiety states and depressive illnesses. II | Q70479385 | ||
| Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study | Q71579723 | ||
| Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis | Q71922578 | ||
| Sertraline for social phobia: a double-blind, placebo-controlled crossover study | Q72006198 | ||
| Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine | Q72561763 | ||
| Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone | Q73122325 | ||
| The effect of citalopram in panic disorder | Q73787222 | ||
| DELINEATION OF TWO DRUG-RESPONSIVE ANXIETY SYNDROMES | Q76917517 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 94-104 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Depression and Anxiety | Q15716773 |
| P1476 | title | Anxiety disorders and major depression, together or apart | |
| P478 | volume | 14 |
| Q42915996 | An expedient and facile route for the general synthesis of 3-aryl substituted 1,2,3-triazolo[1,5-a][1,4]benzodiazepin-6-ones and 1,2,3-triazolo[1,5-a][1,5]benzodiazocin-7-ones |
| Q36402320 | Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. |
| Q47706097 | Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice |
| Q30476550 | Circadian phase and sex effects on depressive/anxiety-like behaviors and HPA axis responses to acute stress |
| Q34699875 | Cognitive inflexibility in obsessive-compulsive disorder and major depression is associated with distinct neural correlates |
| Q37203226 | Cortisol: the culprit prenatal stress variable |
| Q35607283 | Defining anxious depression: going beyond comorbidity |
| Q48301536 | Differential frontal-striatal and paralimbic activity during reversal learning in major depressive disorder and obsessive-compulsive disorder. |
| Q46906379 | Elevated serum homocysteine levels in male patients with PTSD. |
| Q90409515 | Examination of the Correlation Between Physical and Psychological Measures in Community-Dwelling Older Adults |
| Q53130633 | Factor structure of the Mood and Anxiety Symptom Questionnaire does not generalize to an anxious/depressed sample. |
| Q34414358 | Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. |
| Q38828468 | Investigating the nature of co-occurring depression and anxiety: Comparing diagnostic and dimensional research approaches |
| Q48516790 | Latest guidelines for the management of the anxiety disorders - a report from The International Anxiety Disorders Society Conference, Melbourne 2014. |
| Q45372583 | Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder |
| Q33726185 | Physical inactivity is strongly associated with anxiety and depression in Iraqi immigrants to Sweden: a cross-sectional study |
| Q64081727 | Predicting anxiety from wholebrain activity patterns to emotional faces in young adults: a machine learning approach |
| Q48496769 | Protein biomarkers in a mouse model of extremes in trait anxiety |
| Q46165761 | Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways |
| Q41967131 | Psychological responses after a major, fatal earthquake: the effect of peritraumatic dissociation and posttraumatic stress symptoms on anxiety and depression |
| Q33650769 | Risk factors for an anxiety disorder comorbidity among Thai patients with bipolar disorder: results from the Thai Bipolar Disorder Registry |
| Q53695286 | Sequential Ugi reaction/base-induced ring closing/IAAC protocol toward triazolobenzodiazepine-fused diketopiperazines and hydantoins. |
| Q90138871 | Study of novel triazolo-benzodiazepine analogues as antidepressants targeting by molecular docking and ADMET properties prediction |
| Q64079876 | The Association Between the Sedative Loads and Clinical Severity Indicators in the First-Onset Major Depressive Disorder |
| Q30494504 | The circumplex model of affect: an integrative approach to affective neuroscience, cognitive development, and psychopathology |
| Q36272510 | The epidemiology of long-term benzodiazepine use. |
Search more.